Guidant gets access to Metamorphic's technology:
This article was originally published in Clinica
Guidant is to buy certain technology relating to the development of embolic protection devices from Metamorphic Surgical Devices, according to a 10Q filing submitted to the US Securities and Exchange Commission. If certain milestones are met, Guidant may pay up to $15 million in the fourth quarter and a further $3 million thereafter. Guidant, which is already active in this area, says the technological feasibility of the products has not yet been established. The devices are used to capture particles that become dislodged during vascular surgery that can cause stroke if left untreated.